

---

NARCOTIC DRUGS AND PSYCHOTROPIC  
SUBSTANCES (CONSOLIDATION) (AMENDMENT OF  
SCHEDULE) ORDER 2015

---

The Administrator makes the following order in exercise of powers under section 3(2) of the Narcotic Drugs and Psychotropic Substances (Consolidation) Ordinance 2006<sup>(a)</sup>

**Short title and commencement**

1. This Order may be cited as the Narcotic Drugs and Psychotropic Substances (Consolidation) (Amendment of Schedule) Order 2015 and comes into force on the day after it is published in the Gazette.

**Amendments to First Schedule to Narcotic Drugs and Psychotropic Substances (Consolidation) Ordinance 2006**

2. The First Schedule<sup>(b)</sup> to the Narcotic Drugs and Psychotropic Substances (Consolidation) Ordinance 2006 is amended in accordance with regulations 3 to 5.

**Amendments to Part 1 of First Schedule (Class A drugs)**

3. Part 1 of the First Schedule is amended in accordance with Part 1 of the Schedule to this Order.

**Amendments to Part 2 of First Schedule (Class B drugs)**

4. Part 2 of the First Schedule is amended in accordance with Part 2 of the Schedule to this Order.

**Amendments to Part 3 First Schedule (Class C drugs)**

5. Part 3 of the First Schedule is amended in accordance with Part 3 of the Schedule to this Order.

---

(a) Ordinance 16/2006, as amended by Ordinances 22/2010 and 2/2011.  
(b) The First Schedule was substituted by P.I. 30/2011.

# SCHEDULE

Articles 3 to 5

## Amendments to the First Schedule to the Narcotic Drugs and Psychotropic Substances (Consolidation) Ordinance 2006

### PART 1

Article 3

#### Class A Drugs

1. After “Benzethidine” insert—  
“1-(1-benzofuran-2-yl)-N-methylpropan-2-amine (2-MAPB)”;  
“1-(1-benzofuran-2-yl)propan-2-amine (2-APB)”.
2. After “Metamfetamine racemate” insert—  
“4-methamfetamine”.
3. After “3-Methylthiofentanyl” insert—  
“5,6-Methylenedioxy-2-aminoindane (MDAI)”;  
“4-Methyl-5-(p-tolyl)-4,5-dihydrooxazol-2-amine”.
4. After paragraph 4 insert—  
“**4A.** Any substance not specified in paragraphs 1 to 4 structurally derived from fentanyl by modification in any of the following ways—
  - (a) by replacement of the benzene ring of the phenethyl group by any heteromonocyclic ring, whether or not further substituted in the ring or not;
  - (b) by substitution in the phenethyl group with alkyl, alkenyl, hydroxy, halogeno, haloalkyl or nitro group;
  - (c) by substitution in the piperidine ring with alkyl or alkenyl groups;
  - (d) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl;
  - (e) by substitution at the 4-position of the piperidine ring with any alkoxy-carbonyl or alkoxyalkyl or alcyloxy group;
  - (f) by replacement of the N-propionyl group by another acyl group.  
“**4B.** Any substance not specified in paragraphs 1 to 4A structurally derived from 3-(1-benzoyl) indole or 1H-indol-3-yl-(1-benzyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, akenyl, cycloalkyl-methyl, heterocycloalkyl-methyl, cycloalkyl-ethyl or 2-(4-morphonilyl)ethyl groups, irrespective of whether—
  - (a) there is any further substitution;
  - (b) they form a ring with the existing six-membered indole ring;
  - (c) there is further substitution at the indole ring or the benzene ring ,or both, to any extent.”.
5. For paragraph 5 substitute—  
“**5.** Any substance not listed in paragraphs 1 to 4, other than methoxyphenamine, which has a phenethylamine or any N-alkyl derivative of phenethylamine, a-methylphenethylamine, any N-alkyl derivative of a-methylphenethylamine, a-ethylphenylamine or any N-alkyl derivative of ethyl-phenylamine chemical structure, irrespective of whether—

- (a) the alkyls have any substitution with substitution in the ring by groups of alkyl, or alkyloxy, alkenedioxy or allogenenes (irrespective of whether they have any substitution); or
- (b) there is any further substitution of the ring referred to in sub-paragraph (a) by one or more monohydric groups to any extent, or by the presence of cyclic or aromatic or heterocyclic or heterocyclic aromatic ring concentrated with benzole ring, irrespective of whether the rings have any substitution.”.

6. After paragraph 5 insert—

“**5A.** Any substance not specified in paragraphs 1 to 4 structurally derived from tryptamine or from a tryptamine with a hydroxyl group on the benzene ring by substitution at the nitrogen atom of the sidechain with one or more alkyl groups as well as any ester or ether of such substance.

**5B.** Any substance not specified in paragraphs 1 to 5A structurally derived—

- (a) from tryptamine; or
- (b) from a tryptamine with a hydroxyl group on the benzene ring; or
- (c) by substitution at the compound’s aromatic rings or substitution at the nitrogen atom of the sidechain, or both, with one or more alkyl or alkenyl groups, in addition to any ester or ether of such substance.

**5C.** Any substance not specified in paragraphs 1 to 5B structurally derived from benzofuran by substitution at the furan ring with an aminoalkyl group, irrespective of whether there is further substitution.”.

7. In paragraph 6 for “5” substitute “5C”.

8. In paragraph 7 for “11” substitute “11A”.

## PART 2

Article 4

### Class B Drugs

1. After Ethylmorphine insert—

“Ethylphenidate (EPD)”;

2. After “Fenethylamine” insert—

“g-hydroxybutyric acid (GHB)”;

“[9-Hydroxy-6-methyl-3-[5-[phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-ocrahydrophenanthridin-1-yl]acetate (Levonantradol)”

3. Omit “Metamfetamine”.

4. Omit “Metamfetamine racemate”.

5. After 4-methoxymethcathinone (Methedrone)” insert—

“Methoxetamine”.

6. After “Naphthalen-1-yl-(1-pentylindol-3-yl) methanon) (JWH-018) insert—

“1-Naphthalenyl[4-pentyl-1-yl]-1-naphthalenyl]-methanone (CB-13)”.

7. For paragraph 4 substitute—

**“4.** Any substance not listed in paragraphs 1 to 3 containing a 3-(1-naphthoyl)indole or 1H-indole-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen of the indole ring by an alkyl, alkenyl, cycloalkyl methyl, cycloalkyl ethyl or 2-(4-morpholinyl)ethyl group, irrespective of whether—

- (a) there is any further substitution;
- (b) they form a ring with the existing six-membered indole;
- (c) there is any further substitution in the indole ring or the naphthalene ring, or both, to any extent.”.

**8.** After paragraph 4 insert—

**“4A.** Any substance not listed in paragraphs 1 to 3 containing a 3-(1-benzoyl)indole or 1H-indole-3-yl-(1-benzyl)methane structure with substitution at the nitrogen of the indole ring by an alkyl, alkenyl, cycloalkyl methyl, cycloalkyl ethyl or 2-(4-morpholylyl)ethyl group, irrespective of whether—

- (a) there is any further substitution;
- (b) they form a ring with the existing six-membered indole ring; or
- (c) there is any further substitution in the indole ring or the benzole ring, or both, to any extent.

**4B.** Any substance not listed in paragraphs 1 to 4B structurally derived from 3-(1-naphthoyl) indole or 1H-indole-3-yl-(1-naphthyl) methane or 3-(1-naphthyl) carboxylate-indole by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylethyl, alkyl benzyl or 2-(4-morpholinyl)ethyl group irrespective of whether—

- (a) there is any further substitution;
- (b) they form a ring with the existing six-membered indole ring; or
- (c) there is any further substitution in the indole ring and or the naphthalene ring, or both, to any extent.”.

**9.** For paragraph 7 substitute—

**“7.** Any substance not listed in paragraphs 1 to 3 containing a 3-phenylacetyl indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group, irrespective of whether—

- (a) there is any further substitution;
- (b) they form a ring with the existing six-membered indole ring; or
- (c) there is any further substitution in the indole ring or in the benzene or naphthalene ring, or both, to any extent.”.

**10.** For paragraph 8 substitute—

**“8.** Any substance not listed in paragraphs 1 to 3 containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, alkenyl or cycloalkylmethyl, cycloalkylethyl group, irrespective of whether—

- (a) there is any further substitution;
- (b) there is any further substitution on the cyclohexane ring; or
- (c) any substitution forms a ring with the existing phenolic ring, irrespective of whether the ring is substituted.”.

**11.** After paragraph 11 insert—

**“11A.** Any substance not listed in paragraphs 1 to 3 which has an indole-3-carbaldehyde or indazole-3-carbaldehyde chemical structure with substitution at the aldehyde carbon by a cyclic ring, or adamantane ring or 1-aminoadamantane ring (where the nitrogen atom is

connected with the carbonyl carbon) and with substitution at the indole nitrogen or at the indazole ring nitrogen (position 1) by an alkyl, alkene, cycloalkyl methyl, cycloalkyl ethyl or 2-(4-morpholinyl)ethyl group, irrespective of whether—

- (a) there is any further substitution; or
- (b) there is any further substitution to any extent—
  - (i) in the indole or indazole ring;
  - (ii) in the cyclic ring;
  - (iii) in the adamantane ring; or
  - (iv) in the 1-aminoadamantane ring to any degree.”.

### PART 3

Article 5

#### Class C drugs

1. Omit “g-hydroxybutyric acid (GHB)”.

---

Dated this 5 of March 2015

M. Wigston,  
Administrator,  
Sovereign Base Areas.

---

## **EXPLANATORY NOTE**

*(This note is not part of the Order)*

1. This explanatory note relates to the Narcotic Drugs and Psychotropic Substances (Consolidation) (Amendment of Schedule) Order 2015 (“the Order”). It has been prepared by the Office of the Attorney General and Legal Adviser in order to assist the reader of the Order. It does not form part of the Order.
2. The Order amends the Narcotic Drugs and Psychotropic Substances (Consolidation) Ordinance 2006 (“the Ordinance”). It amends the First Schedule to the Ordinance. This Schedule specifies those drugs which are controlled drugs under the Ordinance. The Order reflects amendments made by the Republic’s Public Instruments Numbers 264/2012, 506/2012, 67/2013 162/2013 and 262/2014.

SBA/AG/2/CR/208/1

---

Published by the Sovereign Base Areas Administration  
The Sovereign Base Areas Gazette may be viewed on the official Sovereign Base Areas  
Administration

web site: <http://sbaadministration.org/>